VGF and Alzheimer disease: In AD pathogenesis, VGF was highlighted as a potential therapeutic target as the protein, and its active peptides were reported to reduce amyloid plaques and decrease neuritic dystrophy (el Gaamouch et al., 2020; Quinn et al., 2021).